Loading
A phase 2 trial of Alcestobart run by BeiGene, completed.
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06010303 by BeiGene, with 118 participants enrolled, started 2023-11-08. Conditions recorded: Esophageal Cancer, Esophageal Squamous Cell Carcinoma and Esophageal Squamous Cell Carcinoma by AJCC V8 Stage. Interventions recorded: LBL-007, Tislelizumab and Chemotherapy Doublet.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Alcestobart, Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs, Oesophageal squamous cell carcinoma and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/